We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The company’s earnings surprise history has not been impressive so far, with its earnings beating the Zacks Consensus Estimate in three of the trailing four quarters and missing the same once, the average surprise being -4.70%. In the last-reported quarter, Incyte delivered an earnings miss of 88.10%.
Shares of Incyte have rallied 1% in the year so far against the industry’s decrease of 17.3%.
Image Source: Zacks Investment Research
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Incyte primarily derives product revenues from sales of its lead drug, Jakafi (ruxolitinib), in the United States, and from those of Iclusig. Patient demand for Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]) increased sequentially in the fourth quarter. The trend most likely continued in the to-be-reported quarter as well.
Jakafi sales grew year over year in the previous quarter, which is expected to have continued in the first quarter. The Zacks Consensus Estimate for Jakafi sales stands at $549 million.
Incyte also earns product royalty revenues from Novartis AG (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets. Novartis licensed ruxolitinib from Incyte for development and commercialization outside the United States.
Incyte is likely to have received higher royalties from NVS in the first quarter.
Incyte also receives royalties from sales of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer. Its partner, Novartis, has exclusive worldwide development and commercialization rights to Tabrecta.
Jakafi sales and royalties are key catalysts for the company’s revenue growth. Iclusig sales and Olumiant royalties from Eli Lilly also contribute to the top line. Hence, these are likely to have aided the company’s revenues in the to-be-reported quarter.
Net product revenues of Iclusig were down year over year in the previous quarter, and a similar trend is likely to have been witnessed by INCY in the to-be-reported quarter.
Olumiant’s product royalty revenues were up significantly due to an increase in net product sales as a result of the use of Olumiant for the treatment of COVID-19. Similar levels of growth are likely to have boosted the top line in the to-be-reported quarter.
Incremental sales from newly approved drugs are likely to have boosted sales in the first quarter as well.
Operating expenses are likely to have increased due to a rise in R&D expenses, and selling, general and administrative expenses.
Key Pipeline Updates
Apart from the top- and bottom-line numbers, we expect investors to focus on the company’s pipeline updates.
In March 2022, the FDA extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream.
The sNDA is seeking approval of the cream for the treatment of vitiligo. The regulatory body has extended the target action date by three months to Jul 18, 2022, which was previously set at Apr 18, 2022.
Also, during the same time, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the approval of Jakavi (name outside the United States) to treat patients aged 12 years and older with acute graft versus host disease or chronic GvHD who have an inadequate response to corticosteroids or other systemic therapies.
Per the company, a potential approval will make Jakavi the first JAK1/2 inhibitor available for patients with GvHD in Europe.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Incyte this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Incyte is +11.89% as the Zacks Consensus Estimate is pegged at 57 cents per share while the Most Accurate Estimate is 64 cents.
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has an Earnings ESP of +0.87% and a Zacks Rank #2.
Vertex has an excellent track record, with the company exceeding earnings expectations in each of the trailing four quarters. VRTX delivered a four-quarter earnings surprise of 10.01%, on average. Earnings estimates for 2022 have gone up from $14.52 to $14.56 over the past 60 days. Vertex’s stock has risen 21.9% year to date.
Biogen Inc. (BIIB - Free Report) has an Earnings ESP of +1.32% and a Zacks Rank #3.
Biogen has an excellent track record, with the company exceeding earnings expectations in each of the trailing four quarters. BIIB delivered a four-quarter earnings surprise of 11.72%, on average. Earnings estimates for 2022 are down from $15.84 to $15.38 over the past 60 days.
Image: Shutterstock
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte Corporation (INCY - Free Report) is scheduled to release first-quarter 2022 results on May 3, before the market opens.
The company’s earnings surprise history has not been impressive so far, with its earnings beating the Zacks Consensus Estimate in three of the trailing four quarters and missing the same once, the average surprise being -4.70%. In the last-reported quarter, Incyte delivered an earnings miss of 88.10%.
Shares of Incyte have rallied 1% in the year so far against the industry’s decrease of 17.3%.
Image Source: Zacks Investment Research
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Incyte primarily derives product revenues from sales of its lead drug, Jakafi (ruxolitinib), in the United States, and from those of Iclusig. Patient demand for Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]) increased sequentially in the fourth quarter. The trend most likely continued in the to-be-reported quarter as well.
Jakafi sales grew year over year in the previous quarter, which is expected to have continued in the first quarter. The Zacks Consensus Estimate for Jakafi sales stands at $549 million.
Incyte also earns product royalty revenues from Novartis AG (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets. Novartis licensed ruxolitinib from Incyte for development and commercialization outside the United States.
Incyte is likely to have received higher royalties from NVS in the first quarter.
Incyte also receives royalties from sales of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer. Its partner, Novartis, has exclusive worldwide development and commercialization rights to Tabrecta.
Jakafi sales and royalties are key catalysts for the company’s revenue growth. Iclusig sales and Olumiant royalties from Eli Lilly also contribute to the top line. Hence, these are likely to have aided the company’s revenues in the to-be-reported quarter.
Net product revenues of Iclusig were down year over year in the previous quarter, and a similar trend is likely to have been witnessed by INCY in the to-be-reported quarter.
Olumiant’s product royalty revenues were up significantly due to an increase in net product sales as a result of the use of Olumiant for the treatment of COVID-19. Similar levels of growth are likely to have boosted the top line in the to-be-reported quarter.
Incremental sales from newly approved drugs are likely to have boosted sales in the first quarter as well.
Operating expenses are likely to have increased due to a rise in R&D expenses, and selling, general and administrative expenses.
Key Pipeline Updates
Apart from the top- and bottom-line numbers, we expect investors to focus on the company’s pipeline updates.
In March 2022, the FDA extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream.
The sNDA is seeking approval of the cream for the treatment of vitiligo. The regulatory body has extended the target action date by three months to Jul 18, 2022, which was previously set at Apr 18, 2022.
Also, during the same time, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the approval of Jakavi (name outside the United States) to treat patients aged 12 years and older with acute graft versus host disease or chronic GvHD who have an inadequate response to corticosteroids or other systemic therapies.
Per the company, a potential approval will make Jakavi the first JAK1/2 inhibitor available for patients with GvHD in Europe.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Incyte this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Incyte is +11.89% as the Zacks Consensus Estimate is pegged at 57 cents per share while the Most Accurate Estimate is 64 cents.
Zacks Rank: INCY currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte Corporation Price and EPS Surprise
Incyte Corporation price-eps-surprise | Incyte Corporation Quote
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has an Earnings ESP of +0.87% and a Zacks Rank #2.
Vertex has an excellent track record, with the company exceeding earnings expectations in each of the trailing four quarters. VRTX delivered a four-quarter earnings surprise of 10.01%, on average. Earnings estimates for 2022 have gone up from $14.52 to $14.56 over the past 60 days. Vertex’s stock has risen 21.9% year to date.
Biogen Inc. (BIIB - Free Report) has an Earnings ESP of +1.32% and a Zacks Rank #3.
Biogen has an excellent track record, with the company exceeding earnings expectations in each of the trailing four quarters. BIIB delivered a four-quarter earnings surprise of 11.72%, on average. Earnings estimates for 2022 are down from $15.84 to $15.38 over the past 60 days.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.